2098724-83-3

2098724-83-3 structure
2098724-83-3 structure
  • Name: Abelacimab
  • Chemical Name: Abelacimab
  • CAS Number: 2098724-83-3
  • Molecular Formula:
  • Molecular Weight:
  • Catalog: Signaling Pathways Metabolic Enzyme/Protease Factor Xa
  • Create Date: 2023-01-15 11:34:56
  • Modify Date: 2024-01-03 18:57:16
  • Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies[1][2].

Name Abelacimab
Description Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies[1][2].
Related Catalog
In Vitro Abelacimab (MAA868) (0.0001-1 μM) 以浓度依赖的方式延长凝血时间并减少人血浆中的凝血酶数量[1]。
In Vivo Abelacimab (MAA868) (s.c., 3-30 mg/kg, on day 1, 85, 114) 在食蟹猴中表现出强烈和持续的抗凝血作用,显着延长 aPTT,且具有较好的安全性,未观察到显着的毒性发现或出血迹象[1]。 Abelacimab (MAA868) (i.v., 0.6 mg/kg) 在氯化铁诱导的血栓形成 FXI-/- C57BL/6 小鼠模型中表现出良好的抗凝血活性,以防止颈动脉阻塞[1]。
References

[1]. Alexander W Koch, et al. MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood. 2019 Mar 28;133(13):1507-1516.  

[2]. Elena Campello, et al. Clinical Pharmacology of Factor XI Inhibitors: New Therapeutic Approaches for Prevention of Venous and Arterial Thrombotic Disorders. J Clin Med. 2022 Oct 26;11(21):6314.  

No Any Chemical & Physical Properties